The Medical Advisor

In this interview (below), Dr. Stasha Gominak, 1   a neurologist and sleep coach, explains the curious synergy between vitamin D deficiency, a changed microbiome and poor sleep. I met Dr Gominak at the American College for the Advancement in Medicine’s annual meeting in 2019 in Nashville. Her lecture was about ways to improve your sleep. I thought I was aware of most of them, but the connection between vitamin D and sleep surprised me. Gominak’s research suggests lack of vitamin D causes impairment in your brain stem’s ability to produce normal sleep. So far, she’s treated more than 7,000 patients with her innovative “sleep repair” approach. She’s also published scientific papers on her theories. Vitamin D Deficiency Linked to Sleep Disorders Gominak had no interest in vitamin D, initially. She was fascinated by sleep, and was trying to figure out why so many young and otherwise healthy patients were having such trouble sleeping. Many also had sleep apnea. Over time, it be...

In this interview, Russel Reiter, Ph.D. — a world-class expert on melatonin — discusses some of the biological activities and health benefits of this important molecule. With some 1,600 papers to his credit, as well as three honorary doctor of medicine(1) degrees, he’s published more studies on melatonin than anyone else alive. Melatonin 101 Melatonin is one of the most important antioxidant molecules and certainly the most ancient, as it has been part of biological life for over 3 billion years. It's present in prokaryotes, which are bacteria, and even in plants. In the human body — aside from having direct antioxidant effects — it also stimulates the synthesis of glutathione and other important antioxidants like superoxide dismutase and catalase. Reiter continues:  “Melatonin has been here forever ... and its functions have evolved. It has learned to work successfully with other molecules during this three-billion-year evolution. One of the molecules with wh...

Abstract Background: Lung cancer, particularly advanced or metastatic non–small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), remains a leading cause of cancer mortality worldwide. Conventional therapies such as targeted agents, immunotherapy, and chemotherapy offer survival benefits but often yield limited results in treatment-resistant or late-stage disease. Repurposing widely available antiparasitic drugs — fenbendazole , ivermectin , and mebendazole — has garnered attention in integrative oncology communities due to reported anticancer effects in preclinical studies and emerging anecdotal clinical observations. Objective: To summarize a compilation of real-world case reports describing the use of fenbendazole, ivermectin, and mebendazole in lung cancer patients, highlighting reported clinical outcomes and therapeutic contexts. Methods: This review synthesizes case narratives and outcome descriptions publicly shared through online platforms, including clinicians...